Novo Nordisk

Oral Solid-Dosage Manufacturing Facility Upfit

This Oral Solid-Dose (OSD) Manufacturing Facility Upfit was provided to support Novo Nordisk’s recently acquired facility. The facility is capable of producing OSD products at a capacity of approximately 1.1 billion tablets a year. Various portions of the existing facility were modified to meet Novo Nordisk’s new requirements providing for additional ISO 8 manufacturing space, CNC support space, and open office areas. This facility will manufacture Rybelsus® — Novo Nordisk’s cutting-edge OSD tablet to treat Type 2 Diabetes.

  • Architect/Engineer — SSOE Group
  • Service — Construction Management
  • Repeat Client